<DOC>
	<DOCNO>NCT01903408</DOCNO>
	<brief_summary>For patient prostate cancer high risk lymph node involvement confirm pelvic lymph node metastasis , radiotherapy whole pelvis treatment option . However , conventional radiotherapy pelvis limit gastrointestinal urogenital side effect . The PLATIN trial investigate intensity-modulated radiotherapy pelvic lymphatic drainage spare small bowel , bladder rectum . A high dose give session prostate prostate bed confirm lymph node metastasis . Prior radiotherapy , two month neoadjuvant antihormonal treatment require , continuation radiotherapy two year strongly recommend .</brief_summary>
	<brief_title>Radiotherapy Prostate Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment</brief_title>
	<detailed_description>The PLATIN trial design prospective , non-randomized , five-arm trial . Arm 1 : Definitive radiotherapy pelvic lymphatic drainage integrate boost prostate . Arm 2 : As arm 1 , additional boost macroscopic lymph node metastasis . Arm 3 : Postoperative radiotherapy pelvic lymphatic drainage integrate boost prostate bed . Arm 4 : As arm 3 , additional boost macroscopic lymph node metastasis . Arm 5 : Patients previous radiotherapy prostate bed . Radiotherapy pelvic lymphatic drainage previous treatment field integrate boost macroscopic lymph node metastasis .</detailed_description>
	<criteria>histologically confirm prostate cancer Gleason Score risk lymph node involvement &gt; 20 % ( accord Roach Formula ) , pelvic lymph node metastases CT/MRI histologically confirm lymph node involvement Karnofsky Index &gt; /= 70 % age 1875 year neoadjuvant antihormonal treatment 2 month , continuation end radiotherapy write informed consent stage IV ( distant metastasis ) lymph node metastasis outside pelvis rise prostatespecific antigen ( PSA ) antihormonal treatment severe wound complication laparatomy severe lymph edema leg , elephantiasis , postthrombotic syndrome decompensated comorbidity lung , heart , metabolic system , hematopoetic system kidney , coagulopathy history malignancy within last 5 year ( except basal cell carcinoma squamous carcinoma skin ) previous irradiation pelvic lymph node concurrent participation clinical trial might influence result either trial</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>